Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 49.30
-1.70 (-3.33%)
At close: Dec 4, 2025
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.81B BDT in the quarter ending September 30, 2025, with 31.69% growth. This brings the company's revenue in the last twelve months to 9.52B, up 28.58% year-over-year. In the fiscal year ending June 30, 2025, Navana Pharmaceuticals had annual revenue of 8.84B with 28.19% growth.
Revenue (ttm)
9.52B
Revenue Growth
+28.58%
P/S Ratio
0.56
Revenue / Employee
1.98M
Employees
4,798
Market Cap
5.30B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grameenphone | 156.83B |
| Square Pharmaceuticals PLC. | 80.13B |
| Robi Axiata PLC. | 97.63B |
| British American Tobacco Bangladesh Company | 87.62B |
| BRAC Bank PLC. | 74.07B |
| Walton Hi-Tech Industries | 73.19B |
| Bangladesh Export Import Company | 17.72B |
| Marico Bangladesh | 18.02B |